Stuart B. Mitchell
The world of medical technology has long been highly competitive and tightly regulated. Within such a landscape, true breakthroughs are rare. Novuson, a U.S.-based surgical device company founded in 2014, is positioning itself as one of those rare disruptors, with a technology platform that challenges the fundamentals of how surgeons operate. At its core is a simple but powerful idea: replacing traditional electrical and mechanical energy with sound.
The company was born out of research conducted at the University of Washington’s Applied Physics Laboratory, where early work on therapeutic ultrasound laid the foundation for what would become Novuson’s proprietary Direct Therapeutic Ultrasound (DTU) technology. Designed to address the most persistent risks in surgery, collateral damage and uncontrolled bleeding, DTU enables surgeons to cut and seal tissue without passing electrical current through the body or causing excessive tissue damage. This distinction is critical, as conventional electrosurgical tools can generate excess heat, cause collateral tissue damage, and produce surgical smoke that obscures visibility.
Leading this effort is founder and CEO Stuart B. Mitchell, PhD, a biomedical engineer with a long track record in developing medical instrumentation and translating complex science into clinical solutions. His vision for Novuson is rooted in both innovation and necessity. “We intend to revolutionize surgical safety and precision,” Mitchell has said, reflecting a belief that the operating room is overdue for a step change rather than incremental improvement.
Novuson’s DTU platform represents that step change. By using focused ultrasound energy, the technology allows for precise coagulation and sealing of blood vessels while minimizing thermal spread. This approach has the potential to significantly reduce intraoperative blood loss, shorten procedure times, and improve overall patient outcomes. It also aligns with the growing demand for minimally invasive and robotic-assisted surgeries, where precision and control are paramount.
The company’s product pipeline reflects this focus. Devices such as its UltraStat systems have been engineered for laparoscopic and robotic procedures, combining compact design with high performance. These tools are intended not only to enhance surgical accuracy but also to reduce complications, which remain a major cost driver in healthcare systems worldwide. In this sense, Novuson’s innovation is as much about economics as it is about clinical advancement.
From its earliest days, Novuson has followed a path familiar to many successful medtech ventures: rigorous research, strategic funding, and gradual progression toward commercialization. The company has secured support from both public and private sources, including grants from the U.S. National Institutes of Health to explore applications of its technology in high-risk procedures such as neonatal surgery. These endorsements highlight both the credibility of Novuson’s science and the urgency of the problem it seeks to solve.
Mitchell has consistently emphasized the broader impact of the company’s work. The goal, he has noted, is to “reduce morbidity and mortality associated with surgical procedures,” particularly in cases where even minor improvements in bleeding control can have life-saving implications. This focus on clinical outcomes has helped shape Novuson’s development strategy, ensuring that innovation remains closely aligned with real-world medical needs.
At the same time, the company has attracted strategic investment to accelerate its growth and prepare for market entry. Partnerships with global industry players have provided not only capital but also access to manufacturing expertise and distribution networks, key advantages in an industry where scaling a product can be as challenging as inventing it.
As Novuson moves closer to full commercialization, it faces the same hurdles as any emerging medtech company: regulatory approval, physician adoption, and competition from established players. Yet its differentiation is clear. By eliminating electrical current and excessive heat from the surgical equation and replacing it with precisely controlled ultrasound energy, the company offers a fundamentally new approach to tissue interaction.
In an era where many innovations focus on incremental gains, Novuson’s ambition stands out. It is not simply improving existing tools but redefining the underlying technology. If successful, its approach could reshape surgical standards and open the door to safer, more efficient procedures across a wide range of specialties.
For Mitchell and his team, the mission remains grounded in impact. The promise of Novuson is not just technological elegance, but tangible improvements in patient care. And in a field where outcomes can mean the difference between life and death, that promise carries significant weight.
